WO2006091646A2 - Small molecule inhibitors of mdm2 and uses thereof - Google Patents
Small molecule inhibitors of mdm2 and uses thereof Download PDFInfo
- Publication number
- WO2006091646A2 WO2006091646A2 PCT/US2006/006221 US2006006221W WO2006091646A2 WO 2006091646 A2 WO2006091646 A2 WO 2006091646A2 US 2006006221 W US2006006221 W US 2006006221W WO 2006091646 A2 WO2006091646 A2 WO 2006091646A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- chz
- formula
- cor
- conr
- Prior art date
Links
- 0 C[C@@](*)N(*)[C@@]([C@](C)(/C1=C/C=C/C(/O*)=C\C=C1\O1)C1=O)S Chemical compound C[C@@](*)N(*)[C@@]([C@](C)(/C1=C/C=C/C(/O*)=C\C=C1\O1)C1=O)S 0.000 description 20
- SEMQYGQZVATQOM-TZWBJRETSA-N CC(C)(C)/C=C/[C@H](C([C@H]1c2cc(Cl)ccc2)(C(C(N2)=C3)=CCC3=[ClH])C2=O)N[C@H]1C(N1CCOCC1)=O Chemical compound CC(C)(C)/C=C/[C@H](C([C@H]1c2cc(Cl)ccc2)(C(C(N2)=C3)=CCC3=[ClH])C2=O)N[C@H]1C(N1CCOCC1)=O SEMQYGQZVATQOM-TZWBJRETSA-N 0.000 description 1
- NEVPAVDPZMGBNA-QNONIOJKSA-N CC(C)(C)CC([C@H](C(N(C)C)=O)N[C@H]1c(cc2)ccc2Cl)[C@@]1(c(ccc(Cl)c1)c1N1)C1=O Chemical compound CC(C)(C)CC([C@H](C(N(C)C)=O)N[C@H]1c(cc2)ccc2Cl)[C@@]1(c(ccc(Cl)c1)c1N1)C1=O NEVPAVDPZMGBNA-QNONIOJKSA-N 0.000 description 1
- RUMZPSYCNSSVAN-VPWSAJBTSA-N CC(C)(C)CC([C@]([C@H]1c(cccc2F)c2F)(c(c(N2)c3)ccc3Cl)C2=O)N[C@H]1C(N(C)C)=O Chemical compound CC(C)(C)CC([C@]([C@H]1c(cccc2F)c2F)(c(c(N2)c3)ccc3Cl)C2=O)N[C@H]1C(N(C)C)=O RUMZPSYCNSSVAN-VPWSAJBTSA-N 0.000 description 1
- BVPDTZUBRIKZGL-HDDFQFQDSA-N CC(C)(C)CC([C@]([C@H]1c2cnccc2)(c(c(N2)c3)ccc3Cl)C2=O)N[C@H]1C(N(C)C)=O Chemical compound CC(C)(C)CC([C@]([C@H]1c2cnccc2)(c(c(N2)c3)ccc3Cl)C2=O)N[C@H]1C(N(C)C)=O BVPDTZUBRIKZGL-HDDFQFQDSA-N 0.000 description 1
- HJNRABRZFRPBPV-WZRJCJTJSA-N CC(C)(C)C[C@@]([C@@H]([C@H]1c(cccc2Cl)c2F)C(Nc2c3)=O)(c2ccc3Cl)N[C@H]1C(NCCOCCOC)=O Chemical compound CC(C)(C)C[C@@]([C@@H]([C@H]1c(cccc2Cl)c2F)C(Nc2c3)=O)(c2ccc3Cl)N[C@H]1C(NCCOCCOC)=O HJNRABRZFRPBPV-WZRJCJTJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- This invention is in the field of medicinal chemistry.
- the invention relates to small molecules which function as antagonists of the interaction between p53 and MDM2 and their use as a new class of therapeutics for the treatment of cancer and other diseases.
- the aggressive cancer cell phenotype is the result of a variety of genetic and epigenetic alterations leading to deregulation of intracellular signaling pathways (Ponder, Nature 411:336 (2001)).
- the commonality for all cancer cells is their failure to execute an apoptotic program, and lack of appropriate apoptosis due to defects in the normal apoptosis machinery is a hallmark of cancer (Lowe et ai, Carcinogenesis 27:485 (2000)).
- the inability of cancer cells to execute an apoptotic program due to defects in the normal apoptotic machinery is thus often associated with an increase in resistance to chemotherapy, radiation, or immunotherapy-induced apoptosis.
- the p53 tumor suppressor plays a central role in controlling cell cycle progression and apoptosis (Vogelstein et al, Nature 408:307 (2000)). It is an attractive therapeutic target for anticancer drug design because its tumor suppressor activity can be stimulated to eradicate tumor cells (Vogelstein et al, Nature 408:307 (2000); Chene, Nat. Rev. Cancer 3:102 (2003)).
- a new approach to stimulating the activity of p53 is through inhibition of its interaction with the protein MDM2 using non-peptide small molecule inhibitors (Chene, Nat. Rev. Cancer 3:102 (2003); Vassilev et al, Science 303:844 (2004)).
- MDM2 and p53 are part of an auto-regulatory feed-back loop (Wu et al, Genes Dev. 7:1126 (1993)). MDM2 is transcriptionally activated by p53 and MDM2, in turn, inhibits p53 activity by at least three mechanisms (Wu et al, Genes Dev. 7:1126 (1993). First, MDM2 protein directly binds to the p53 transactivation domain and thereby inhibits p53- mediated transactivation. Second, MDM2 protein contains a nuclear export signal sequence, and upon binding to ⁇ 53, induces the nuclear export of p53, preventing p53 from binding to the targeted DNAs.
- MDM2 protein is an E3 ubiquitin ligase and upon binding to p53 is able to promote p53 degradation.
- MDM2 effectively inhibits p53-mediated apoptosis, cell cycle arrest and DNA repair. Therefore, small-molecule inhibitors that bind to MDM2 and block the interaction between MDM2 and ⁇ 53 can promote the activity of p53 in cells with a functional p53 and stimulate p53-mediated cellular effects such as cell cycle arrest, apoptosis, or DNA repair (Chene, Nat. Rev. Cancer 3:102 (2003); Vassilev et al, Science 303:844 (2004))
- the present invention contemplates that exposure of animals suffering from cancer to therapeutically effective amounts of drug(s) [e.g., small molecules) that increase the function(s) of p53 and p53-related proteins (e.g., p63, p73) by inhibiting the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins (e.g., MDMX) will inhibit the growth of cancer cells or supporting cells outright and/or render such cells as a population more susceptible to the cell death-inducing activity of cancer therapeutic drugs or radiation therapies.
- the inhibitors of the invention may prolong the half-life of p53 by interfering with the p53-MDM2 interaction that would normally promote degradation of p53.
- the present invention contemplates that inhibitors of the interaction between p53 or p53- related proteins and MDM2 and MDM2-related proteins satisfy an unmet need for the treatment of multiple cancer types, either when administered as monotherapy to induce cell growth inhibition, apoptosis and/or cell cycle arrest in cancer cells, or when administered in a temporal relationship with additional agent(s), such as other cell death-inducing or cell cycle disrupting cancer therapeutic drugs or radiation therapies (combination therapies), so as to render a greater proportion of the cancer cells or supportive cells susceptible to executing the apoptosis program compared to the corresponding proportion of cells in an animal treated only with the cancer therapeutic drug or radiation therapy alone.
- additional agent(s) such as other cell death-inducing or cell cycle disrupting cancer therapeutic drugs or radiation therapies (combination therapies)
- combination treatment of animals with a therapeutically effective amount of a compound of the present invention and a course of an anticancer agent or radiation produces a greater tumor response and clinical benefit in such animals compared to those treated with the compound or anticancer drugs/radiation alone.
- the compounds will lower the apoptotic threshold of all cells, the proportion of cells that will successfully execute the apoptosis program in response to the apoptosis inducing activity of anticancer drugs/radiation is increased.
- the compounds of the present invention will be used to allow administration of a lower, and therefore less toxic and more tolerable, dose of an anticancer agent and/or radiation to produce the same tumor response/clinical benefit as the conventional dose of the anticancer agent/radiation alone. Since the doses for all approved anticancer drugs and radiation treatments are known, the present invention contemplates the various combinations of them with the present compounds.
- the compounds of the present invention may act at least in part by stimulating the pro-apoptotic and/or cell cycle-inhibiting activities of p53 and p53-related proteins
- the exposure of cancer cells and supporting cells to therapeutically effective amounts of the compounds should be temporally linked to coincide with the attempts of cells to execute the apoptosis program in response to the anticancer agent or radiation therapy.
- administering the compositions of the present invention in connection with certain temporal relationships provides especially efficacious therapeutic practices.
- inhibitors of the interaction between p53 or p53-related proteins and MDM2 and MDM2-related proteins may protect normal (e.g., non-hyperproliferative) cells from the toxic effects of certain chemotherapeutic agents and radiation, possibly through the ability of the inhibitors to induce cell cycle arrest.
- the inhibitors of the invention may cause cell cycle arrest in cells comprising wild-type p53 while having no effect on cancer cells comprising mutated or deleted p53. This differential protective effect may allow for more effective treatment of cancer by allowing the use of higher doses or longer treatments of chemotherapeutic agents or treatments without increasing the toxic side effects of such treatment.
- the present invention relates to compounds that are useful for inhibiting the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins and increasing the sensitivity of cells to inducers of apoptosis and/or cell cycle arrest.
- the compounds have Formula I:
- X is CH, O 5 N, or S, wherein Rg is absent if X is O or S;
- Y is O, S, or NR 1 ;
- Ri, R 2 , R 3 , R 4 , R5, R ⁇ , and R 7 are independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO 2 R',
- R 7 forms an aryl, cycloalkyl, or heterocyclic group with one of Rs or Rg;
- Rg is H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO 2 R', OCOR 1 , CONR 1 R", SO 2 NR 1 R", or
- R 9 is one to four groups independently selected from H, F, Cl, Br, I 5 OH, NO 2 , alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, OR',
- each R', R" and R" 1 is independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or heterocyclic; or
- R 1 and R" form a ring; or when one of R3 and R 4 is CONRR 1 , then one of R and R 1 may further be
- the invention relates to compounds represented by Formula I, which are inhibitors of the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins.
- the invention relates to the use of the compounds of the invention to induce cell cycle arrest and/or apoptosis in cells containing functional p53 or p53-related proteins.
- the invention also relates to the use of the compounds of the invention for sensitizing cells to additional agent(s), such as inducers of apoptosis and/or cell cycle arrest, and chemoprotection of normal cells through the induction of cell cycle arrest prior to treatment with chemotherapeutic agents.
- the invention relates to methods of rendering a normal cell resistant to chemotherapeutic agents or treatments, comprising contacting the cell with a compound of the invention.
- the invention relates to methods of protecting normal cells in an animal with a hyperproliferative disease from the toxic side effects of chemotherapeutic agents or treatments, comprising administering to said animal a compound of the invention.
- the invention is directed to the treatment, amelioration, or prevention of disorders, side effects, or conditions caused by the administration of chemotherapeutic agents to normal noncancerous cells by administering to an animal undergoing chemotherapy a compound of the present invention.
- disorders and conditions caused by chemotherapy include, without limitation, mucositis, stomatitis, xerostomia, gastrointestinal disorders, and alopecia.
- the compounds of the invention are useful for the treatment, amelioration, or prevention of disorders, such as those responsive to induction of apoptotic cell death, e.g., disorders characterized by dysregulation of apoptosis, including hyperproliferative diseases such as cancer.
- the compounds can be used to treat, ameliorate, or prevent cancer that is characterized by resistance to cancer therapies (e.g., those cancer cells which are chemoresistant, radiation resistant, hormone resistant, and the like).
- the compounds can be used to treat hyperproliferative diseases characterized by expression of functional p53 or p53-related proteins.
- the invention relates to the use of the compounds of the invention to protect normal (e.g., non- hyperproliferative) cells from the toxic side effects of chemotherapeutic agents and treatments by the induction of cell cycle arrest in those cells.
- the present invention provides pharmaceutical compositions comprising a compound of Formula I in a therapeutically effective amount to induce apoptosis in cells or to sensitize cells to inducers of apoptosis.
- kits comprising a compound of Formula
- kits may optionally contain other therapeutic agents, e.g., anticancer agents or apoptosis-modulating agents.
- the invention also provides methods of making compounds of
- Figure 1 shows the design of a new class of MDM2 inhibitors based upon spirotryprostatin A.
- Figures 2A and 2B show the predicted binding model of compounds
- Figure 3 shows the X-ray structure of (1"R,2"S,2'R,3'R,3S,4'R) 6- chloro-4'-(3-chloro-phenyl)-l i -(2-hydroxy-l,2-diphenyl-ethyl)-2'-(3-methyl- butyl)-2-oxo-l,2-dihydro-spiro[indole-3,3'-pyi ⁇ olidine]-5'-carboxylic acid dimethylan ⁇ ide.
- Figure 4A shows the saturation curve of PMDM6-F binding to MDM2 protein.
- Figure 4B shows the competitive binding curves of unlabeled fluorescent probe PMDM6 and native p53 peptide to MDM2 protein.
- Figure 5 shows the competitive binding curves and K,- values of inhibitors of MDM2 as determined using a FP-based binding assay.
- Figure 6 shows the inhibition of cell growth in LNCaP prostate cancer cells with wild-type p53 as determined by a WST cell growth assay.
- Figure 7 shows the inhibition of cell growth in PC3 prostate cancer cells with mutant p53 as determined by a WST cell growth assay.
- Figure 8 shows the inhibition of cell growth in PrEC normal human prostate epithelial cells with wild-type p53 as determined by a WST cell growth assay.
- Figure 9 shows competitive binding curves of several inhibitors of the p53-MDM2 interaction.
- Figure 10 shows the disruption of p53-MDM2 interaction by Ke-43.
- Figure 11 shows the cell growth inhibition activity of Ke-43 in colon cancer cells with or without wild-type p53 and in normal cells.
- Figure 12 shows Western blot analysis of the expression of ⁇ 53 and its target gene products MDM2 and ⁇ 21 in cancer cells in response to Ke-43.
- Figures 13A and 13B show cell death and apoptosis induced by Ke-43 and Ke-61 in cancer cells and normal cells.
- Figure 14 shows cell cycle progression of colon cancer cell lines expressing wild-type p53 or mutant p53 and normal colon cells after treatment with Ke-43 and nutlin-3.
- Figures 15 shows protection of normal cells from TAXOL treatment by Ke-63. DETAILED DESCRIPTION OF THE INVENTION
- the present invention relates to compounds represented by Formula I, which function as inhibitors of the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins.
- compounds represented by Formula I By inhibiting the negative effect of MDM2 or MDM2-related proteins on p53 or p53-related proteins, these compounds sensitize cells to inducers of apoptosis and/or cell cycle arrest and, in some instances, themselves induce apoptosis and/or cell cycle arrest.
- the invention relates to methods of sensitizing cells to inducers of apoptosis and/or cell cycle arrest and to methods of inducing apoptosis and/or cell cycle arrest in cells, comprising contacting the cells with a compound of Formula I alone or in combination with additional agent(s), e.g., an inducer of apoptosis or a cell cycle disrupter.
- additional agent(s) e.g., an inducer of apoptosis or a cell cycle disrupter.
- the invention further relates to methods of treating, ameliorating, or preventing disorders in an animal, such as those that are responsive to induction of apoptosis, comprising administering to the animal a compound of Formula I and additional agent(s), e.g., an inducer of apoptosis.
- Such disorders include those characterized by a dysregulation of apoptosis and those characterized by the proliferation of cells expressing functional p53 or p53-related proteins.
- the invention relates to methods of protecting normal (e.g., non- hyperproliferative) cells in an animal from the toxic side effects of chemotherapeutic agents and treatments comprising administering to the animal a compound of Formula I.
- anticancer agent and “anticancer drug,” as used herein, refer to any therapeutic agents (e.g., chemotherapeutic compounds and/or molecular therapeutic compounds), antisense therapies, radiation therapies, or surgical interventions, used in the treatment of hyperproliferative diseases such as cancer (e.g. , in mammals).
- therapeutic agents e.g., chemotherapeutic compounds and/or molecular therapeutic compounds
- antisense therapies e.g., radiation therapies, or surgical interventions, used in the treatment of hyperproliferative diseases such as cancer (e.g. , in mammals).
- prodrug refers to a pharmacologically inactive derivative of a parent “drug” molecule that requires biotransformation (e.g., either spontaneous or enzymatic) within the target physiological system to release, or to convert (e.g., enzymatically, physiologically, mechanically, electromagnelically) the prodrug into the active drug.
- Prodrugs are designed to overcome problems associated with stability, toxicity, lack of specificity, or limited bioavailability.
- Exemplary prodrugs comprise an active drug molecule itself and a chemical masking group (e.g., a group that reversibly suppresses the activity of the drug).
- Some preferred prodrugs are variations or derivatives of compounds that have groups cleavable under metabolic conditions.
- Exemplary prodrugs become pharmaceutically active in vivo or in vitro when they undergo solvolysis under physiological conditions or undergo enzymatic degradation or other biochemical transformation (e.g., phosphorylation, hydrogenation, dehydrogenation, glycosylation).
- Prodrugs often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism. (See e.g., Bundgard, Design of Prodrugs, pp. 7-9, 21- 24, Elsevier, Amsterdam (1985); and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA (1992)).
- Common prodrugs include acid derivatives such as esters prepared by reaction of parent acids with a suitable alcohol (e.g., a lower alkanol), amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative (e.g., a lower alkylamide).
- a suitable alcohol e.g., a lower alkanol
- amides prepared by reaction of the parent acid compound with an amine amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative (e.g., a lower alkylamide).
- acylated base derivative e.g., a lower alkylamide
- pharmaceutically acceptable salt refers to any salt (e.g., obtained by reaction with an acid or a base) of a compound of the present invention that is physiologically tolerated in the target animal (e.g., a mammal). Salts of the compounds of the present invention may be
- acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, sulfonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
- Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and compounds of formula NW 4 + , wherein W is Ci -4 alkyl, and the like.
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- W is Ci -4 alkyl
- salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, chloride, bromide, iodide, 2-hydtoxyethanesulfonate, lactate, maleate, mesylate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate
- salts include anions of the compounds of the present invention compounded with a suitable cation such as Na + , NfLj + , and NW 4 + (wherein W is a C ⁇ alkyl group), and the like.
- a suitable cation such as Na + , NfLj + , and NW 4 + (wherein W is a C ⁇ alkyl group), and the like.
- salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
- salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
- a therapeutically effective amount refers to that amount of the therapeutic agent sufficient to result in amelioration of one or more symptoms of a disorder, or prevent advancement of a disorder, or cause regression of the disorder.
- a therapeutically effective amount preferably refers to the amount of a therapeutic agent that decreases the rate of tumor growth, decreases tumor mass, decreases the number of metastases, increases time to tumor progression, or increases survival time by at least 5%, preferably at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%.
- sensitize and “sensitizing,” as used herein, refer to making, through the administration of a first agent (e.g., a compound of Formula I), an animal or a cell within an animal more susceptible, or more responsive, to the biological effects (e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell division, cell growth, proliferation, invasion, angiogenesis, necrosis, or apoptosis) of a second agent.
- a first agent e.g., a compound of Formula I
- biological effects e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell division, cell growth, proliferation, invasion, angiogenesis, necrosis, or apoptosis
- the sensitizing effect of a first agent on a target cell can be measured as the difference in the intended biological effect (e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell growth, proliferation, invasion, angiogenesis, or apoptosis) observed upon the administration of a second agent with and without administration of the first agent.
- the response of the sensitized cell can be increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 350%, at least 300%, at least 350%, at least 400%, at least 450%, or at least 500% over the response in the absence of the first agent.
- the term "dysregulation of apoptosis,” as used herein, refers to any aberration in the ability of (e.g., predisposition) a cell to undergo cell death via apoptosis.
- Dysregulation of apoptosis is associated with or induced by a variety of conditions, non-limiting examples of which include, autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, graft- versus-host disease, myasthenia gravis, or Sjogren's syndrome), chronic inflammatory conditions (e.g., psoriasis, asthma or Crohn's disease), hyperproliferative disorders (e.g., tumors, B cell lymphomas, or T cell lymphomas), viral infections (e.g., herpes, papilloma, or HIV), and other conditions such as osteoarthritis and atherosclerosis. It should be noted that when the dysregulation is induced by or
- the term "functional p53,” as used herein, refers to wild-type p53 expressed at normal, high, or low levels and mutant p53 that retains at least 5% of the activity of wild-type p53, e.g., at least 10%, 20%, 30%, 40%, 50%, or more of wild-type activity.
- p53-related protein refers to proteins that have at least 25% sequence homology with p53, have tumor suppressor activity, and are inhibited by interaction with MDM2 or MDM2-related proteins.
- p53-related proteins include, but are not limited to, p63 and p73.
- MDM2-related protein refers to proteins that have at least 25% sequence homology with MDM2, and interact with and inhibit p53 or p53-related proteins.
- MDM2-related proteins include, but are not limited to, MDMX and HDM2.
- hyperproliferative disease refers to any condition in which a localized population of proliferating cells in an animal is not governed by the usual limitations of normal growth.
- hyperproliferative disorders include tumors, neoplasms, lymphomas and the like.
- a neoplasm is said to be benign if it does not undergo invasion or metastasis and malignant if it does either of these.
- a "metastatic" cell means that the cell can invade and destroy neighboring body structures.
- Hyperplasia is a form of cell proliferation involving an increase in cell number in a tissue or organ without significant alteration in structure or function.
- Metaplasia is a form of controlled cell growth in which one type of fully differentiated cell substitutes for another type of differentiated cell.
- autoimmune disorder refers to any condition in which an organism produces antibodies or immune cells which recognize the organism's own molecules, cells or tissues.
- Non-limiting examples of autoimmune disorders include autoimmune hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, Fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, vitiligo, and the like.
- neoplastic disease refers to any abnormal growth of cells being either benign (non-cancerous) or malignant (cancerous).
- normal cell refers to a cell that is not undergoing abnormal growth or division. Normal cells are non-cancerous and are not part of any hyperproliferative disease or disorder.
- anti-neoplastic agent refers to any compound that retards the proliferation, growth, or spread of a targeted (e.g., malignant) neoplasm.
- prevention refers to a decrease in the occurrence of pathological cells (e.g., hyperproliferative or neoplastic cells) in an animal.
- the prevention may be complete, e.g., the total absence of pathological cells in a subject.
- the prevention may also be partial, such that the occurrence of pathological cells in a subject is less than that which would have occurred without the present invention.
- apoptosis-modulating agents refers to agents which are involved in modulating (e.g., inhibiting, decreasing, increasing, promoting) apoptosis.
- apoptosis-modulating agents include proteins which comprise a death domain such as, but not limited to, Fas/CD95, TRAMP, TNF RI, DRl, DR2, DR3, DR4, DR5, DR6, FADD, and RIP.
- apoptosis-modulating agents include, but are not limited to, TNFo; Fas ligand, antibodies to Fas/CD95 and other TNF family receptors, TRAIL (also known as Apo2 Ligand or Apo2L/TRAIL), antibodies to TRAIL-Rl or TRAIL-R2, Bcl-2, p53, BAX, BAD, Akt, CAD, PI3 kinase, PPl, and caspase proteins.
- Modulating agents broadly include agonists and antagonists of TNF family receptors and TNF family ligands.
- Apoptosis- modulating agents may be soluble or membrane bound ⁇ e.g. ligand or receptor).
- apoptosis-modulating agents are inducers of apoptosis, such as TNF or a TNF-related ligand, particularly a TRAMP ligand, a Fas/CD95 ligand, a TNFR-I ligand, or TRAIL.
- inducers of apoptosis such as TNF or a TNF-related ligand, particularly a TRAMP ligand, a Fas/CD95 ligand, a TNFR-I ligand, or TRAIL.
- the inhibitors of the interaction between p53 and MDM2 of the present invention are compounds of Formula I:
- X is CH, O, N, or S, wherein Rg is absent if X is O or S;
- Y is O, S, or NR'
- Ri, R 2 , R 3 , R 4 , R 5 , R ⁇ j and R 7 are independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO 2 R',
- R 7 forms an aryl, cycloalkyl, or heterocyclic group with one of Rs or R ⁇ ;
- Rs is H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO 2 R', OCOR', CONR'R", SO 2 NR 1 R", or
- R 9 is one to four groups independently selected from H, F, Cl, Br, I, OH, NO 2 , alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, OR',
- one of Ri and R 2 is a substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted heteroaryl, cycloalkyl, straight or branched alkyl, amide or ester.
- aryl e.g., phenyl
- heteroaryl e.g., cycloalkyl
- straight or branched alkyl e.g., amide or ester
- one of R 5 and Re is a C 3 - 18 alkyl group, e.g., propyl, isopropyl, sec-butyl, tert-butyl, isopentyl, cyclopentyl, norbornyl, or adamantyl, or a 5- or 6-membered aiyl or heteroaryl group.
- R 5 and Re is a C 3 - 18 alkyl group, e.g., propyl, isopropyl, sec-butyl, tert-butyl, isopentyl, cyclopentyl, norbornyl, or adamantyl, or a 5- or 6-membered aiyl or heteroaryl group.
- the compounds of Formula I have a stereochemical structure as shown in Formula II or Formula III:
- the compounds of Formula I have Formula IV:
- the compounds of Formula IV have a stereochemical structure as shown in Formula V or Formula VI:
- the compounds of Formula I have Formula VII:
- the compounds of Formula VII have a stereochemical structure as shown in Formula VIII or Fo ⁇ nula IX:
- the compounds of Formula I have Fo ⁇ nula X:
- Ri, Rs, R 7 , and R 9 are as defined above;
- Rio and Rn are independently H, OH or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, (CHa) n -R 1 , (CH 2 ) n -NR'R", (CH 2 ) n -NR'COR", (CHa) n -NR 1 SO 2 R", (CHa) n -
- Z is O, NH, NR', CH 2 , CHR', or CR 1 R"; and Ri, R5, R 7 , R 9 , and Rio are as defined above.
- the compounds of Formula I have one of
- Ri, R 3 , R 9 , and Rg are as defined above;
- R 12 is one to four groups independently selected from H, F, Cl, Br, I, OH, NO 2 , alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, OR', CO 2 R', OCOR 1 , CONR 1 R", NR 11 COR 1 , NR 1 SO 2 R", SO 2 NR 1 R", (ONR)NR 11 R" 1 , or NR 1 R"; and n is O, 1, or 2.
- Ri, R 3 , R 4 , R 5 and Rg are as defined above.
- the compounds of Formula I have one of
- R 1 , R 4 , R 5 , R9, Rio, and Rn are as defined above.
- the compounds of Formula I have one of
- Ri, R 4 , Rs, R9, Rio, and Rn are as defined above.
- the compounds of Formula I have one of
- Useful alkyl groups include straight-chained or branched CM S alkyl groups, especially methyl, ethyl, propyl, isopropyl, t-butyl, sec-butyl, 3-pentyl, adamantyl, norbornyl, and 3-hexyl groups.
- Useful alkenyl groups include straight-chained or branched C 2 - 18 alkyl groups, especially ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, and hexenyl.
- Useful alkynyl groups are C 2 - 18 alkynyl groups, especially ethynyl, propynyl, butynyl, and 2-butynyl groups
- Useful cycloalkyl groups are C ⁇ cycloalkyl. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- Useful aryl groups include C 6 - 14 aryl, especially phenyl, naphthyl, phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups.
- Useful heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl,
- heteroaryl group contains a nitrogen atom in a ring
- nitrogen atom may be in the form of an N-oxide, e.g., a pyridyl N- oxide, pyrazinyl N-oxide, pyrimidinyl N-oxide, and the like.
- Useful heterocyclic groups include tetrahydrofuranyl, pyranyl, piperidinyl, piperizinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, isochiOmanyl, chromanyl, pyrazolidinyl, pyrazolinyl, tetronoyl, tetramoyl, or tetrahydroisoquinolinyl groups, as well as heterocyclic groups fused with a heteroaryl ring, e.g., optionally substituted 5,6-dihydro-8H-[l,2,4]triazolo[4,3-A]pyrazinyl.
- Optional substituents include one or more alkyl; halo; haloalkyl; cycloalkyl; aryl optionally substituted with one or more lower alkyl, lower alkoxy, methylenedioxy, halo, haloalkyl, aminosulfonyl, aryl, or heteroaryl groups; aryloxy optionally substituted with one or more lower alkyl, lower alkoxy, methylenedioxy, halo, haloalkyl, aminosulfonyl, aryl, or heteroaryl groups; aralkyl; heteroaryl optionally substituted with one or more lower alkyl, lower alkoxy, methylenedioxy, halo, haloalkyl, aminosulfonyl, aryl, or heteroaryl groups; heteroaryloxy optionally substituted with one or more lower alkyl, lower alkoxy, methylenedioxy, halo, haloalkyl, aminosulfonyl,
- Certain of the compounds of the present invention may exist as stereoisomers including optical isomers.
- the invention includes all stereoisomers, both as pure individual stereoisomer preparations and enriched preparations of each, and both the racemic mixtures of such stereoisomers as well as the individual enantiomers that may be separated according to methods that are well known to those of skill in the art.
- Reagents and conditions a) CH 2 Cl 2 -CH 3 CN, KF-Al 2 O 3 , microwave, or methanol, piperidine reflux; b) 4A molecular sieves, toluene, 7O 0 C; c) amine, r.t; d) Pb(OAc) 4 , CH 2 Cl 2 -MeOH (1 : 1), 0 0 C, or ammonium cerium(IV) nitrate (CAN), CH 3 CN, K 2 CO 3 , r.t.
- Reagents and conditions a) CH 2 Cl 2 -CH 3 CN, KF-Al 2 O 3 , microwave, or methanol, piperidine reflux; b) 4A molecular sieves, toluene, 7O 0 C; c) amine, r.t; d) Pb(OAc) 4 , CH 2 Cl 2 -MeOH (1:1), 0 0 C, or ammonium cerium(IV) nitrate (CAN), CH 3 CN, K 2 CO 3 , r.t.
- the invention relates to a method of preparing a compound having formula X, comprising a) condensing a compound of Formula 1 with a compound of Formula 2, e.g., in a solvent or a mixture of solvents ⁇ e.g., CH 2 Cl 2 and CH 3 CN) under microwave in the presence of a catalyst ⁇ e.g., KF-Al 2 O 3 ) or in the presence of a base in a suitable solvent to form a compound of Formula 3;
- a catalyst e.g., KF-Al 2 O 3
- a dehydrating agent e.g., 4 A molecular sieve
- Ri, and R 5 are independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO 2 R', OCOR', CONR 1 R",
- R 9 is one to four groups independently selected from H, F, Cl, Br, I, OH, NO 2 , alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, OR', CO 2 R 1 , OCOR 1 , CONR 1 R", NR 11 COR 1 , NR 1 SO 2 R", SO 2 NR 1 R", (ONR 1 JNR 11 R" 1 , or NR 1 R";
- Rio and Rn are independently H, OH or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, (Ct ⁇ ⁇ -R 1 , (CHi) n -NR 1 R 11 , (CH 2 ) n -NR'C0R", (CHa) n -NR 1 SO 2 R", (CH 2 ) n -
- the invention in another embodiment, relates to a method of preparing a compound having formula LXV, comprising a) condensing a compound of Formula 16 with a compound of Formula 2, e.g., in a solvent or a mixture of solvents (e.g., CH 2 Cl 2 and CH 3 CN) under microwave in the presence of a catalyst (e.g., KF-Al 2 Os) or in the presence of a base in a suitable solvent to form a compound of Formula 17;
- a catalyst e.g., KF-Al 2 Os
- the invention relates to a method of preparing a compound having formula XXIX, comprising a) condensing a compound of Fo ⁇ nula 3 with a compound of Formula 4 and a compound of Formula 5, e.g., in a non-polar solvent ⁇ e.g., toluene) in the presence of a dehydrating agent ⁇ e.g., Ak molecular sieve) or by azeotropic distillation at elevated temperature ⁇ e.g., about 7O 0 C) to form a compound of Formula 7;
- a dehydrating agent e.g., Ak molecular sieve
- azeotropic distillation at elevated temperature ⁇ e.g., about 7O 0 C
- a blocking agent e.g., a trialkyl silyl halide such as TBDMSCl
- a polar solvent e.g., DMF
- trimethylacetyl chloride or other protective agents in a solvent or a mixture of solvents (e.g., diisopropyl ethylamine, CH 2 CI 2 ) and then acid (e.g., HCl) to form a compound of Fo ⁇ nula 10;
- alkylating the compound of Formula 13 with an alkylating agent e.g., HCHO, NaBH 3 CN, and CH 3 CN
- an alkylating agent e.g., HCHO, NaBH 3 CN, and CH 3 CN
- Formula I induce cell cycle arrest and/or apoptosis and also potentiate the induction of cell cycle arrest and/or apoptosis either alone or in response to additional apoptosis induction signals. Therefore, it is contemplated that these compounds sensitize cells to induction of cell cycle arrest and/or apoptosis, including cells that are resistant to such inducing stimuli.
- the inhibitors of the interaction between p53 or p53-related proteins and MDM2 or MDM2-realted proteins of the present invention can be used to induce apoptosis in any disorder that can be treated, ameliorated, or prevented by the induction of apoptosis. In one embodiment, the inhibitors can be used to induce apoptosis in cells comprising functional p53 or ⁇ 53-related proteins.
- the invention pertains to modulating an apoptosis associated state which is associated with one or more apoptosis- modulating agents.
- apoptosis-modulating agents include, but are not limited to, Fas/CD95, TRAMP, TNF RI, DRl, DR2, DR3, DR4, DR5, DR6, FADD, RJP, TNF ⁇ , Fas ligand, TRAIL, antibodies to TRAIL-Rl or TRAIL-R2, Bcl-2, p53, BAX, BAD, Alct, CAD, PB kinase, PPl, and caspase proteins.
- apoptosis-modulating agents include agents, the activity, presence, or change in concentration of which, can modulate apoptosis in a subject.
- Preferred apoptosis-modulating agents are inducers of apoptosis, such as TNF or a TNF-related ligand, particularly a TRAMP ligand, a Fas/CD95 ligand, a TNFR-I ligand, or TRAIL.
- compositions and methods of the present invention are used to treat diseased cells, tissues, organs, or pathological conditions and/or disease states in an animal (e.g., a mammalian subject including, but not limited to, humans and veterinary animals).
- an animal e.g., a mammalian subject including, but not limited to, humans and veterinary animals.
- various diseases and pathologies are amenable to treatment or prophylaxis using the present methods and compositions.
- a non-limiting exemplary list of these diseases and conditions includes, but is not limited to, breast cancer, prostate cancer, lymphoma, skin cancer, pancreatic cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leuk
- infections suitable for treatment with the compositions and methods of the present invention include, but are not limited to, infections caused by viruses, bacteria, fungi, mycoplasma, prions, and the like.
- Some embodiments of the present invention provide methods for administering an effective amount of a compound of Formula I and at least one additional therapeutic agent (including, but not limited to, chemotherapeutic antineoplastics, apoptosis-modulating agents, antimicrobials, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (e.g., surgical intervention, and/or radiotherapies).
- additional therapeutic agent including, but not limited to, chemotherapeutic antineoplastics, apoptosis-modulating agents, antimicrobials, antivirals, antifungals, and anti-inflammatory agents
- therapeutic technique e.g., surgical intervention, and/or radiotherapies.
- anticancer agents are contemplated for use in the methods of the present invention. Indeed, the present invention contemplates, but is not limited to, administration of numerous anticancer agents such as: agents that induce apoptosis; polynucleotides (e.g., anti-sense, ribozymes, siRNA); polypeptides (e.g., enzymes and antibodies); biological mimetics (e.g., gossypol or BH3 mimetics); agents that bind (e.g., oligomerize or complex) with a Bcl-2 family protein such as Bax; alkaloids; alkylating agents; antitumor antibiotics; antimetabolites; hormones; platinum compounds; monoclonal or polyclonal antibodies (e.g., antibodies conjugated with anticancer drugs, toxins, defensins), toxins; radionuclides; biological response modifiers ⁇ e.g., interferons (e.g., IFN- ⁇ )
- anticancer agents
- anticancer agents comprise agents that induce or stimulate apoptosis.
- Agents that induce apoptosis include, but are not limited to, radiation (e.g., X-rays, gamma rays, UV); tumor necrosis factor (TNF)-related factors (e.g., TNF family receptor proteins, TNF family ligands, TRAIL, antibodies to TRAIL-Rl or TRAIL-R2); kinase inhibitors (e.g., epidermal growth factor receptor (EGFR) kinase inhibitor, vascular growth factor receptor (VGFR) kinase inhibitor, fibroblast growth factor receptor (FGFR) kinase inhibitor, platelet-derived growth factor receptor (PDGFR) kinase inhibitor, and Bcr-Abl kinase inhibitors (such as GLEEVEC)); antisense molecules; antibodies (e.g., HERCEPTIN, RITUXAN, ZEVALIN, and AV
- compositions and methods of the present invention provide a compound of Formula I and at least one anti- hyperproliferative or antineoplastic agent selected from alkylating agents, antimetabolites, and natural products (e.g., herbs and other plant and/or animal derived compounds).
- at least one anti- hyperproliferative or antineoplastic agent selected from alkylating agents, antimetabolites, and natural products (e.g., herbs and other plant and/or animal derived compounds).
- Alkylating agents suitable for use in the present compositions and methods include, but are not limited to: 1) nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, ifosfamide, melphalan (L-sarcolysin); and chlorambucil); 2) ethylenimines and methylmelamines (e.g., hexamethylmelamine and thiotepa); 3) alkyl sulfonates (e.g., busulfan); 4) nitrosoureas (e.g., carmustine (BCNU); lomustine (CCNU); semustine (methyl-CCNU); and streptozocin (streptozotocin)); and 5) triazenes (e.g., dacarbazine (DTIC; dimethyltriazenoimid-azolecarboxamide).
- nitrogen mustards e.g., mechlorethamine, cyclophosphamide,
- antimetabolites suitable for use in the present compositions and methods include, but are not limited to: 1) folic acid analogs (e.g., methotrexate (amethopterin)); 2) pyrimidine analogs (e.g., fluorouracil (5-fluorouracil; 5-FU), floxuridine (fluorode-oxyuridine; FudR), and cytarabine (cytosine arabinoside)); and 3) purine analogs (e.g., mercaptopurine (6-merca ⁇ topurine; 6-MP), thioguanine (6-thioguanine; TG), and pentostatin (2 '-deoxycoformycin)).
- folic acid analogs e.g., methotrexate (amethopterin)
- pyrimidine analogs e.g., fluorouracil (5-fluorouracil; 5-FU), floxuridine (fluorode-oxyuridine; FudR), and cytar
- chemotherapeutic agents suitable for use in the compositions and methods of the present invention include, but are not limited to: 1) vinca alkaloids (e.g., vinblastine (VLB), vincristine); 2) epipodophyllotoxins (e.g., etoposide and teniposide); 3) antibiotics (e.g., dactinomycin (actinomycin D), daunorubicin (daunomycin; rubidomycin), doxorubicin, bleomycin, plicamycin (tnithramycin), and mitomycin (mitomycin C)); 4) enzymes (e.g., L-asparaginase); 5) biological response modifiers (e.g., interferon-alfa); 6) platinum coordinating complexes (e.g., cisplatin (cis-DDP) and carboplatin); 7) anthracenediones (e.g., mitoxan
- any oncolytic agent that is routinely used in a cancer therapy context finds use in the compositions and methods of the present invention.
- the U.S. Food and Drug Administration maintains a formulary of oncolytic agents approved for use in the United States. International counterpart agencies to the U.S.F.D.A. maintain similar formularies.
- Table 1 provides a list of exemplary antineoplastic agents approved for use in the U.S. Those skilled in the art will appreciate that the "product labels" required on all U.S. approved chemotherapeutics describe approved indications, dosing information, toxicity data, and the like, for the exemplary agents. Table 1.
- Anticancer agents further include compounds which have been identified to have anticancer activity but are not currently approved by the U.S. Food and Drug Administration or other counterpart agencies or are undergoing evaluation for new uses. Examples include, but are not limited to, 3-AP, ⁇ -O-tetradecanoylphorbol-lS-acetate, 17AAG, 852A, ABI-007, ABR- 217620, ABT-751, ADI-PEG 20, AE-941, AG-013736, AGROlOO, alanosine, AMG 706, antibody G250, antineoplastons, AP23573, apaziquone, APC8015, atiprimod, ATN-161, atrasenten, azacitidine, BB- 10901, BCX-1777, bevacizumab, BGOOOOl, bicalutamide, BMS 247550, bortezomib, bryostatin- 1, buserelin, calcitriol, CCI-779, CDB-2914
- the present invention provides methods for administering a compound of Formula I with radiation therapy.
- the invention is not limited by the types, amounts, or delivery and administration systems used to deliver the therapeutic dose of radiation to an animal.
- the animal may receive photon radiotherapy, particle beam radiation therapy, other types of radiotherapies, and combinations thereof.
- the radiation is delivered to the animal using a linear accelerator.
- the radiation is delivered using a gamma knife.
- the source of radiation can be external or internal to the animal.
- External radiation therapy is most common and involves directing a beam of high-energy radiation to a tumor site through the skin using, for instance, a linear accelerator. While the beam of radiation is localized to the tumor site, it is nearly impossible to avoid exposure of normal, healthy tissue. However, external radiation is usually well tolerated by animals.
- Internal radiation therapy involves implanting a radiation-emitting source, such as beads, wires, pellets, capsules, particles, and the like, inside the body at or near the tumor site including the use of delivery systems that specifically target cancer cells (e.g., using particles attached to cancer cell binding ligands). Such implants can be removed following treatment, or left in the body inactive.
- Types of internal radiation therapy include, but are not limited to, brachytherapy, interstitial irradiation, intracavity irradiation, radioimmunotherapy, and the like.
- the animal may optionally receive radiosensitizers ⁇ e.g., metronidazole, misonidazole, intra-arterial Budr, intravenous iododeoxyuridine (IudR), nitroimidazole, 5-substituted-4-nitroimidazoles 5 2H- isoindolediones, [[(2-bromoethyl)-amino]methyl]-nitro-lH-imidazole-l- ethanol, nitroaniline derivatives, DNA-affmic hypoxia selective cytotoxins, halogenated DNA ligand, 1,2,4 benzotriazine oxides, 2-nitroimidazole derivatives, fluorine-containing nitroazole derivatives, benzamide, nicotinamide, acridine-intercalator, 5-thiotretrazole derivative, 3-nitro-l,2,4- triazole, 4,5-dinitroimidazole derivative, hydroxylated texaph
- Radiotherapy Any type of radiation can be administered to an animal, so long as the dose of radiation is tolerated by the animal without unacceptable negative side-effects.
- Suitable types of radiotherapy include, for example, ionizing (electromagnetic) radiotherapy (e.g., X-rays or gamma rays) or particle beam radiation therapy (e.g., high linear energy radiation).
- Ionizing radiation is defined as radiation comprising particles or photons that have sufficient energy to produce ionization, i.e., gain or loss of electrons (as described in, for example, U.S. 5,770,581 incorporated herein by reference in its entirety).
- the effects of radiation can be at least partially controlled by the clinician.
- the dose of radiation is preferably fractionated for maximal target cell exposure and reduced toxicity.
- the total dose of radiation administered to an animal preferably is about .01 Gray (Gy) to about 100 Gy. More preferably, about 10 Gy to about 65 Gy (e.g., about 15 Gy, 20 Gy, 25 Gy, 30 Gy, 35 Gy, 40 Gy, 45 Gy 5 50 Gy, 55 Gy, or 60 Gy) are administered over the course of treatment. While in some embodiments a complete dose of radiation can be administered over the course of one day, the total dose is ideally fractionated and administered over several days. Desirably, radiotherapy is administered over the course of at least about 3 days, e.g., at least 5, 7, 10, 14, 17, 21, 25, 28, 32, 35, 38, 42, 46, 52, or 56 days (about 1-8 weeks).
- a daily dose of radiation will comprise approximately 1-5 Gy (e.g., about 1 Gy, 1.5 Gy, 1.8 Gy, 2 Gy, 2.5 Gy, 2.8 Gy, 3 Gy, 3.2 Gy, 3.5 Gy, 3.8 Gy, 4 Gy, 4.2 Gy, or 4.5 Gy), preferably 1-2 Gy (e.g., 1.5-2 Gy).
- the daily dose of radiation should be sufficient to induce destruction of the targeted cells.
- radiation preferably is not administered every day, thereby allowing the animal to rest and the effects of the therapy to be realized.
- radiation desirably is administered on 5 consecutive days, and not administered on 2 days, for each week of treatment, thereby allowing 2 days of rest per week.
- radiation can be administered 1 day/week, 2 days/week, 3 days/week, 4 days/week, 5 days/week, 6 days/week, or all 7 days/week, depending on the animal's responsiveness and any potential side effects.
- Radiation therapy can be initiated at any time in the therapeutic period.
- radiation is initiated in week 1 or week 2, and is administered for the remaining duration of the therapeutic period.
- radiation is administered in weeks 1-6 or in weeks 2-6 of a therapeutic period comprising 6 weeks for treating, for instance, a solid tumor.
- radiation is administered in weeks 1-5 or weeks 2-5 of a therapeutic period comprising 5 weeks.
- Antimicrobial therapeutic agents may also be used as therapeutic agents in the present invention. Any agent that can kill, inhibit, or otherwise attenuate the function of microbial organisms may be used, as well as any agent contemplated to have such activities. Antimicrobial agents include, but are not limited to, natural and synthetic antibiotics, antibodies, inhibitory proteins (e.g., defensins), antisense nucleic acids, membrane disruptive agents and the like, used alone or in combination. Indeed, any type of antibiotic may be used including, but not limited to, antibacterial agents, antiviral agents, antifungal agents, and the like.
- Formula I and one or more therapeutic agents or anticancer agents are administered to an animal under one or more of the following conditions: at different periodicities, at different durations, at different concentrations, by different administration routes, etc.
- the compound is administered prior to the therapeutic or anticancer agent, e.g., 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks prior to the administration of the therapeutic or anticancer agent.
- the compound is administered after the therapeutic or anticancer agent, e.g., 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks after the administration of the anticancer agent.
- the compound and the therapeutic or anticancer agent are administered concurrently but on different schedules, e.g., the compound is administered daily while the therapeutic or anticancer agent is administered once a week, once every two weeks, once every three weeks, or once every four weeks. In other embodiments, the compound is administered once a week while the therapeutic or anticancer agent is administered daily, once a week, once every two weeks, once every three weeks, or once every four weeks.
- Compositions within the scope of this invention include all compositions wherein the compounds of the present invention are contained in an amount which is effective to achieve its intended purpose. While individual needs vary, dete ⁇ nination of optimal ranges of effective amounts of each component is within the skill of the art.
- the compounds may be administered to mammals, e.g. humans, orally at a dose of 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated for disorders responsive to induction of apoptosis.
- about 0.01 to about 25 mg/kg is orally administered to treat, ameliorate, or prevent such disorders.
- the dose is generally about one-half of the oral dose.
- a suitable intramuscular dose would be about 0.0025 to about 25 mg/kg, and most preferably, from about 0.01 to about 5 mg/kg.
- the unit oral dose may comprise from about 0.01 to about 1000 mg, preferably about 0.1 to about 100 mg of the compound.
- the unit dose may be administered one or more times daily as one or more tablets or capsules each containing from about 0.1 to about 10 mg, conveniently about 0.25 to 50 mg of the compound or its solvates.
- the compound may be present at a concentration of about 0.01 to 100 mg per gram of carrier. In a preferred embodiment, the compound is present at a concentration of about 0.07-1.0 mg/ml, more preferably, about 0.1-0.5 mg/ml, most preferably, about 0.4 mg/ml.
- the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.
- the preparations particularly those preparations which can be administered orally or topically and which can be used for the preferred type of administration, such as tablets, dragees, slow release lozenges and capsules, mouth rinses and mouth washes, gels, liquid suspensions, hair rinses, hair gels, shampoos and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by intravenous infusion, injection, topically or orally, contain from about 0.01 to 99 percent, preferably from about 0.25 to 75 percent of active compound(s), together with the excipient.
- the pha ⁇ naceutical compositions of the invention may be administered to any animal which may experience the beneficial effects of the compounds of the invention.
- animals e.g., humans, although the invention is not intended to be so limited.
- Other animals include veterinary animals (cows, sheep, pigs, horses, dogs, cats and the like).
- the compounds and pharmaceutical compositions thereof may be administered by any means that achieve their intended purpose.
- administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal or topical routes.
- administration may be by the oral route.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- compositions of the present invention are manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes.
- pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
- fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose,
- disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross- linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
- Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
- Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices.
- concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used.
- Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
- Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin.
- stabilizers may be added.
- Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base.
- Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons.
- gelatin rectal capsules which consist of a combination of the active compounds with a base.
- Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
- Suitable fo ⁇ nulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water- soluble salts and alkaline solutions.
- suspensions of the active compounds as appropriate oily injection suspensions may be administered.
- Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
- the suspension may also contain stabilizers.
- the topical compositions of this invention are formulated preferably as oils, creams, lotions, ointments and the like by choice of appropriate carriers.
- Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C 1 2).
- the preferred carriers are those in which the active ingredient is soluble.
- Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired.
- transdermal penetration enhancers can be employed in these topical formulations. Examples of such enhancers can be found in U.S. Pat. Nos. 3,989,816 and 4,444,762.
- Creams are preferably formulated from a mixture of mineral oil, self- emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil such as almond oil, is admixed.
- a typical example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.
- Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil such as almond oil with warm soft paraffin and allowing the mixture to cool.
- a vegetable oil such as almond oil
- a typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight.
- Lotions may be conveniently prepared by dissolving the active ingredient, in a suitable high molecular weight alcohol such as propylene glycol or polyethylene glycol.
- suitable high molecular weight alcohol such as propylene glycol or polyethylene glycol.
- Spirotryprostatin A represents a class of natural alkaloids isolated from the fermentation broth of Aspergillus fiimigatus (Usui et ah, Biochem. J. 33:543 (1998)) (FIG. 1).
- spirotryprostatin A cannot bind in the hydrophobic cleft of MDM2, but the spiro(oxindole-3,3'-pyrrolidine) core structure may be used as a rigid scaffold for the design of a new class of inhibitors of the p53-MDM2 interaction.
- the oxindole unit closely mimics the Trp23 residue in both hydrogen-bond formation and hydrophobic interaction with MDM2.
- The. pyrrolidinyl ring provides a rigid scaffold with which two hydrophobic groups can be attached to mimic Phel9 and Leu26 (FIG. 2A).
- a number of template compounds were modeled using different substituent groups with different configurations.
- compound Ia was shown to mimic p53 well in its hydrogen-bonding and key hydrophobic interactions with MDM2 (FIG. 2A).
- the 6-chloro substituent on the oxindole ring occupies a small hydrophobic pocket in MDM2, an interaction which has been shown to be effective in enhancing the binding affinities of p53 -based peptide inhibitors of MDM2 (Garcia- Echeverria et al, Med. Chein 43:3205 (2000)).
- FP-based binding assay was established using a recombinant human MDM2 protein and a p53 -based peptide (Garcia-Echeverria et al, J Med Cliem 43:3205 (2000)) labeled with a fluorescence tag.
- the fluorescent-probe termed PMDM6-F, had the sequence (5-Fam-/3Ala-/3Ala-Phe-Met-Aib-pTyr-(6-Cl-l-Trp)-Glu-Ac3c-Leu-Asn-NH 2 ) (SEQ ID NO:1), wherein Fam is carboxyfluoroscein, Aib is /3-aminoisobutyric acid, and Ac3c is 1-aminocyclopropane-l-carboxylic acid.
- the Kd value of the binding of this designed probe to MDM2 protein was determined to be 0.001 jtiM (1 nM ⁇ 0.09), showing that this peptide binds to the surface pocket of the MDM2 protein with very high affinity (FIG. 4A).
- the recombinant MDM2 human protein (residues 1-118) fused to His- tag at the N terminus was stable and soluble, and was used for the FP based binding assay.
- the bound peptide control containing MDM2 protein and PMDM6-F (equivalent to 0% inhibition) and free peptide control containing only free PMDM6-F (equivalent to 100% inhibition) were included.
- the polarization values were measured after 3 hrs of incubation when the binding reached equilibrium using an ULTRA READER (Tecan U.S. Inc., Research Triangle Park, NC).
- IC 50 values the inhibitor concentration at which 50% of bound peptide is displaced, were determined from a plot using nonlinear least-squares analysis. Curve fitting was performed using GRAPHPAD PRISM software (GraphPad Software, Inc., San Diego, CA).
- the fluorescently labeled p53-based peptide had a Kj value of 1 nM with MDM2, which is consistent with its previously reported high affinity to MDM2 (Garcia-Echeverria et ah, Med. Chem 43:3205 (2000)).
- a natural p53 peptide (residues 13-29), which was used as a positive control, and Ia were determined to have K; values of 6.7 ⁇ M and 8.5 ⁇ M, respectively (FIG. 5).
- Ia is a fairly potent inhibitor of the p53- MDM2 interaction.
- Ia could be further optimized for better interaction with MDM2.
- the phenyl ring of Ia binds to the hydrophobic binding pocket occupied by the side chain of Phel9 but there is additional space in this pocket.
- the isobutyl group of Ia fills the hydrophobic binding pocket occupied by Leu26 but a larger hydrophobic group could be accommodated.
- New analogues of Ia were designed in an attempt to optimize further the interactions at these two hydrophobic binding sites.
- Non-peptide small-molecule inhibitors over peptide-based inhibitors is their superior cell permeability. It is predicted that potent, non-peptide inhibitors of the p53-MDM2 interaction such as Id will be effective in inhibition of cell growth and division in cancer cells with a wild- type form of p53 through stimulation of the activity of p53. Furthermore, they are predicted to have selectivity in cancer cells with either a loss of p53 or a mutated, non-functional form of p53. To test these predictions, a cell growth assay was developed using human prostate cancer LNCaP ( ⁇ 53 wild-type) and PC-3 (p53 null) cell lines. The toxic effects of compounds on normal cells were also examined on a normal prostate epithelial cell line.
- the absorbance of the samples was measured at 450 nm in a plate reader (Molecular Device-TECAN ULTRA).
- concentration of the compounds that inhibited cell growth by 50% was calculated by comparing absorbance in the untreated cells and the cells treated with the compounds. The compounds induced cell growth inhibition in a dose-dependent fashion.
- PROPYL -2-OXO-l,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-
- PROPYL -2-OXO-l,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-
- N-methyl-glycine (14 mmol) and 3-methyl-but-2-enal (14 mmol) in 100 mL toluene was refluxed for 6 hours.
- the solvent was removed and the residue was purified on silica gel column to yield the product.
- This compound was prepared by hydrogenation of the compound of example 50.
- PROPYL -2-OXO-l,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-
- PROPYL -2-OXO-l,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-
- PROPYL)-AMIDE KE-78
- PROPYL)-AMIDE KE-IOl
- PROPYL -5'-METHYLCARBAMOYL-2-OXO-l,2-DIHYDRO- SPIRO[INDOLE-3,3'-PYRROLIDINE]- ⁇ -CARBOXYLIC ACID METHYL
- PROPYL -2-OXO-l,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ561215A NZ561215A (en) | 2005-02-22 | 2006-02-22 | Small molecule inhibitors of MDM2 and uses thereof |
CN2006800129073A CN101160314B (en) | 2005-02-22 | 2006-02-22 | Small molecule inhibitors of mdm2 and the uses thereof |
EP06735754.1A EP1856123B1 (en) | 2005-02-22 | 2006-02-22 | Small molecule inhibitors of mdm2 and uses thereof |
BRPI0609172-5A BRPI0609172A2 (en) | 2005-02-22 | 2006-02-22 | mdm2 small molecule inhibitors and uses of these |
AU2006216780A AU2006216780B8 (en) | 2005-02-22 | 2006-02-22 | Small molecule inhibitors of MDM2 and uses thereof |
EA200701771A EA014445B1 (en) | 2005-02-22 | 2006-02-22 | Small molecule inhibitors of mdm2 and uses thereof |
JP2007556414A JP5248866B2 (en) | 2005-02-22 | 2006-02-22 | MDM2 small molecule inhibitors and uses thereof |
MX2007010272A MX2007010272A (en) | 2005-02-22 | 2006-02-22 | Small molecule inhibitors of mdm2 and uses thereof. |
CA2598690A CA2598690C (en) | 2005-02-22 | 2006-02-22 | Small molecule inhibitors of mdm2 and uses thereof |
NO20074853A NO20074853L (en) | 2005-02-22 | 2007-09-24 | Smamolecule inhibitors of MDM2 and applications thereof |
AU2010202759A AU2010202759B2 (en) | 2005-02-22 | 2010-06-30 | Small molecule inhibitors of MDM2 and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65513505P | 2005-02-22 | 2005-02-22 | |
US60/655,135 | 2005-02-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006091646A2 true WO2006091646A2 (en) | 2006-08-31 |
WO2006091646A3 WO2006091646A3 (en) | 2006-11-30 |
Family
ID=36927977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/006221 WO2006091646A2 (en) | 2005-02-22 | 2006-02-22 | Small molecule inhibitors of mdm2 and uses thereof |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1856123B1 (en) |
JP (2) | JP5248866B2 (en) |
KR (1) | KR100944301B1 (en) |
CN (2) | CN102627649B (en) |
AU (2) | AU2006216780B8 (en) |
BR (1) | BRPI0609172A2 (en) |
CA (2) | CA2598690C (en) |
EA (2) | EA019566B1 (en) |
MX (1) | MX2007010272A (en) |
NO (1) | NO20074853L (en) |
WO (1) | WO2006091646A2 (en) |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008072655A1 (en) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | Imidazothiazole derivatives |
WO2008144507A2 (en) * | 2007-05-16 | 2008-11-27 | President And Fellows Of Harvard College | Spirooxindole inhibitors of aurora kinase |
EP2063887A2 (en) * | 2006-08-30 | 2009-06-03 | The Regents of the University of Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
WO2009151069A1 (en) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | Imidazothiazole derivative having 4,7-diazaspiro[2.5]octane ring structure |
JP2010504298A (en) * | 2006-09-21 | 2010-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | Oxindole derivatives |
WO2010031713A1 (en) | 2008-09-18 | 2010-03-25 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
JP2010509260A (en) * | 2006-11-09 | 2010-03-25 | エフ.ホフマン−ラ ロシュ アーゲー | Spiroindolinone derivatives |
US7700641B2 (en) | 2005-04-11 | 2010-04-20 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their uses as therapeutic agents |
JP2010527954A (en) * | 2007-05-23 | 2010-08-19 | エフ.ホフマン−ラ ロシュ アーゲー | Spiroindolinone derivatives |
US7799798B2 (en) | 2005-04-11 | 2010-09-21 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
JP2011506524A (en) * | 2007-12-19 | 2011-03-03 | エフ.ホフマン−ラ ロシュ アーゲー | Spiroindolinone derivatives |
US7928233B2 (en) | 2009-02-10 | 2011-04-19 | Hoffmann-La Roche Inc. | Spiroindolinone pyridine derivatives |
WO2011045257A1 (en) * | 2009-10-14 | 2011-04-21 | F. Hoffmann-La Roche Ag | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions |
WO2011061139A1 (en) * | 2009-11-17 | 2011-05-26 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
WO2011067185A1 (en) * | 2009-12-02 | 2011-06-09 | F. Hoffmann-La Roche Ag | Spiroindolinone pyrrolidines |
WO2011098398A1 (en) * | 2010-02-09 | 2011-08-18 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
WO2011101297A1 (en) * | 2010-02-17 | 2011-08-25 | F. Hoffmann-La Roche Ag | Substituted spiroindolinones |
WO2011134925A1 (en) | 2010-04-28 | 2011-11-03 | F. Hoffmann-La Roche Ag | Spiroindolinone pyrrolidines |
US8053457B2 (en) | 2007-03-29 | 2011-11-08 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
US8088931B2 (en) | 2005-02-22 | 2012-01-03 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
WO2012022707A1 (en) * | 2010-08-18 | 2012-02-23 | F. Hoffmann-La Roche Ag | Substituted heteroaryl spiropyrrolidine mdm2 antagonists |
WO2012034954A1 (en) * | 2010-09-15 | 2012-03-22 | F. Hoffmann-La Roche Ag | Substituted hexahydropyrrolo [1, 2 - c] imidazolones useful as mdm2 inhibitors |
WO2012038307A1 (en) * | 2010-09-20 | 2012-03-29 | F. Hoffmann-La Roche Ag | Spiro substituted pyrrolo[1,2-c]imidazole derivatives useful as mdm2 inhibitors |
US8217051B2 (en) | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
US8263606B2 (en) | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
WO2012121361A1 (en) | 2011-03-10 | 2012-09-13 | 第一三共株式会社 | Dispiropyrrolidine derivative |
WO2012155066A2 (en) | 2011-05-11 | 2012-11-15 | Shaomeng Wang | Spiro-oxindole mdm2 antagonists |
US8445696B2 (en) | 2009-10-14 | 2013-05-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
US8450358B2 (en) | 2009-06-29 | 2013-05-28 | Xenon Pharmaceuticals Inc. | Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents |
US8466188B2 (en) | 2006-10-12 | 2013-06-18 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
CN103435622A (en) * | 2013-07-31 | 2013-12-11 | 陕西科技大学 | Spiro indole diketopiperazine alkaloid, and synthesis method and application of spiro indole diketopiperazine alkaloid |
WO2014038606A1 (en) | 2012-09-06 | 2014-03-13 | 第一三共株式会社 | Crystal of dispiropyrrolidine derivative |
US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
WO2015033974A1 (en) | 2013-09-04 | 2015-03-12 | 第一三共株式会社 | Method for producing spirooxindole derivative |
WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
US9381238B2 (en) | 2010-11-05 | 2016-07-05 | University Of Dundee | Method for improving the production of influenza viruses and vaccine seeds |
US9504671B2 (en) | 2010-02-26 | 2016-11-29 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
WO2017060431A1 (en) | 2015-10-09 | 2017-04-13 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
US9682033B2 (en) | 2015-02-05 | 2017-06-20 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
CN107427501A (en) * | 2015-02-20 | 2017-12-01 | 第三共株式会社 | Integrated processes for treating cancer |
WO2018074387A1 (en) | 2016-10-17 | 2018-04-26 | 第一三共株式会社 | Combination therapy method using mdm2 inhibitor and dna methyltransferase inhibitor |
US10485794B2 (en) | 2015-04-13 | 2019-11-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of MDM2 inhibitor and BTK inhibitor |
RU2717238C2 (en) * | 2015-03-30 | 2020-03-19 | Мишн Терапьютикс Лимитед | Compounds of 1-cyano-pyrrolidines as usp30 inhibitors |
EP3160463B1 (en) | 2014-06-26 | 2020-10-21 | Novartis AG | Intermittent dosing of mdm2 inhibitor |
US10919913B2 (en) | 2014-08-21 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors |
RU2743432C2 (en) * | 2016-04-06 | 2021-02-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Mdm2 protein destructors |
US10981898B2 (en) | 2015-09-29 | 2021-04-20 | Astex Therapeutics Limited | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity |
CN112876488A (en) * | 2021-02-18 | 2021-06-01 | 苏州大学 | Spiro indoline derivative and preparation method and application thereof |
US11236047B2 (en) | 2017-03-28 | 2022-02-01 | Astex Therapeutics Limited | Combination of isoindolinone derivatives with SGI-110 |
US11261171B1 (en) | 2015-09-29 | 2022-03-01 | Astex Therapeutics Limited | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity |
US11603367B2 (en) | 2017-03-28 | 2023-03-14 | Astex Therapeutics Limited | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723372B2 (en) * | 2008-03-19 | 2010-05-25 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
AU2010319595B2 (en) * | 2009-11-12 | 2015-09-17 | The Regents Of The University Of Michigan | Spiro-oxindole MDM2 antagonists |
AU2011237782A1 (en) * | 2010-04-09 | 2012-10-25 | The Regents Of The University Of Michigan | Biomarkers for MDM2 inhibitors for use in treating disease |
WO2012065022A2 (en) * | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
CN102627650B (en) * | 2012-03-08 | 2015-07-08 | 徐州师范大学 | Chiral spiro(pyrrolidine-3, 2'-oxindole)compound and synthesis method thereof |
CN105585570B (en) * | 2015-12-15 | 2019-10-15 | 贵州大学 | Isoxazole splices pyrroles's loop coil Oxoindole compound and preparation method and application |
CN107353292B (en) * | 2017-08-23 | 2018-07-10 | 山东博苑医药化学有限公司 | Acyl in loop coil Oxoindole second(Sulphur)Urea derivative and preparation method thereof and the application in terms of prevention plant virus, sterilization, desinsection |
CN108486041A (en) * | 2018-03-28 | 2018-09-04 | 华南农业大学 | Application and its detection method of the PI3K/Akt signal paths in chicken embryo fibroblasts to marek virus proliferation |
CN110680838B (en) * | 2019-11-21 | 2021-10-01 | 海门茂发美术图案设计有限公司 | Application of vegetarian calycanthine in resisting prostate cancer |
CN115417871B (en) * | 2022-09-21 | 2023-06-02 | 成都理工大学 | Double spiro pyrrolospirone oxindole compound, synthesis method and antifungal activity thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051360A1 (en) | 2001-12-18 | 2003-06-26 | F. Hoffmann-La Roche Ag | Cis-imidazolines as mdm2 inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3219661A (en) * | 1962-12-14 | 1965-11-23 | Warner Lambert Pharmaceutical | Spirooxindole and spirodehydroindole alkaloids and process therefor |
GB1056537A (en) * | 1963-07-16 | 1967-01-25 | Smith Kline French Lab | Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof |
JPH0423184A (en) * | 1990-05-18 | 1992-01-27 | Toshiba Corp | Optical character reader |
JP3074281B2 (en) * | 1990-05-30 | 2000-08-07 | 住友大阪セメント株式会社 | Flexible container |
JPH07238069A (en) * | 1994-02-28 | 1995-09-12 | Daicel Chem Ind Ltd | Production of cyclic amide compound |
RU2084449C1 (en) * | 1994-03-02 | 1997-07-20 | Всероссийский научный центр по безопасности биологически активных веществ | 1-benzyl-2-oxotryptamine hydrochloride and its derivatives showing hepatoprotective activity |
US5773455A (en) * | 1996-06-28 | 1998-06-30 | Biomeasure, Incorporated | Inhibitors of prenyl transferases |
DE59814452D1 (en) * | 1997-01-20 | 2010-06-24 | Immodal Pharmaka Gmbh | METHOD AND SUBSTANCES FOR RELEASING A GROWTH FACTOR FROM ENDOTHELIAL CELLS AND UNDER THE PROCESS RELEASED GROWTH FACTOR AND ITS USE |
CN1265665A (en) * | 1997-06-10 | 2000-09-06 | 葛兰素集团有限公司 | Benzimidazole derivatives |
WO1999012904A1 (en) * | 1997-09-08 | 1999-03-18 | Arqule, Inc. | Spiro[pyrrolidine-2,3'-oxindole] compounds and methods of use |
CN1182083C (en) * | 2001-10-08 | 2004-12-29 | 廖宜芳 | Complex fertilizer for killing insect and bacteria and its production method |
-
2006
- 2006-02-22 CA CA2598690A patent/CA2598690C/en not_active Expired - Fee Related
- 2006-02-22 KR KR1020077021939A patent/KR100944301B1/en not_active IP Right Cessation
- 2006-02-22 CN CN201210066457.3A patent/CN102627649B/en not_active Expired - Fee Related
- 2006-02-22 EA EA201001255A patent/EA019566B1/en not_active IP Right Cessation
- 2006-02-22 EA EA200701771A patent/EA014445B1/en not_active IP Right Cessation
- 2006-02-22 EP EP06735754.1A patent/EP1856123B1/en active Active
- 2006-02-22 BR BRPI0609172-5A patent/BRPI0609172A2/en not_active IP Right Cessation
- 2006-02-22 WO PCT/US2006/006221 patent/WO2006091646A2/en active Application Filing
- 2006-02-22 CN CN2006800129073A patent/CN101160314B/en not_active Expired - Fee Related
- 2006-02-22 AU AU2006216780A patent/AU2006216780B8/en not_active Ceased
- 2006-02-22 MX MX2007010272A patent/MX2007010272A/en active IP Right Grant
- 2006-02-22 JP JP2007556414A patent/JP5248866B2/en not_active Expired - Fee Related
- 2006-02-22 CA CA2752738A patent/CA2752738C/en not_active Expired - Fee Related
-
2007
- 2007-09-24 NO NO20074853A patent/NO20074853L/en not_active Application Discontinuation
-
2010
- 2010-06-30 AU AU2010202759A patent/AU2010202759B2/en not_active Ceased
-
2012
- 2012-04-06 JP JP2012086927A patent/JP5638023B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051360A1 (en) | 2001-12-18 | 2003-06-26 | F. Hoffmann-La Roche Ag | Cis-imidazolines as mdm2 inhibitors |
Non-Patent Citations (5)
Title |
---|
CHENE, NAT. REV. CANCER, vol. 3, 2003, pages 102 |
GOODMAN; GILMAN'S ET AL.: "Pharmaceutical Basis of Therapeutics", 2002 |
KUSSIE ET AL., SCIENCE, vol. 274, 1996, pages 948 |
See also references of EP1856123A4 |
YASSILEV ET AL., SCIENCE, vol. 303, 2004, pages 844 |
Cited By (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8742121B2 (en) | 2005-02-22 | 2014-06-03 | The Regents Of The University Of Michigan | Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein |
US8901117B2 (en) | 2005-02-22 | 2014-12-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
US8088931B2 (en) | 2005-02-22 | 2012-01-03 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
US7935721B2 (en) | 2005-04-11 | 2011-05-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their uses as therapeutic agents |
US7700641B2 (en) | 2005-04-11 | 2010-04-20 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their uses as therapeutic agents |
US7799798B2 (en) | 2005-04-11 | 2010-09-21 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
US8106087B2 (en) | 2005-04-11 | 2012-01-31 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their uses as therapeutic agents |
US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
EP2063887A4 (en) * | 2006-08-30 | 2010-09-22 | Univ Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
EP2063887A2 (en) * | 2006-08-30 | 2009-06-03 | The Regents of the University of Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
JP2010504298A (en) * | 2006-09-21 | 2010-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | Oxindole derivatives |
US8466188B2 (en) | 2006-10-12 | 2013-06-18 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
JP2010509260A (en) * | 2006-11-09 | 2010-03-25 | エフ.ホフマン−ラ ロシュ アーゲー | Spiroindolinone derivatives |
WO2008072655A1 (en) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | Imidazothiazole derivatives |
US8053457B2 (en) | 2007-03-29 | 2011-11-08 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
WO2008144507A3 (en) * | 2007-05-16 | 2009-05-14 | Harvard College | Spirooxindole inhibitors of aurora kinase |
WO2008144507A2 (en) * | 2007-05-16 | 2008-11-27 | President And Fellows Of Harvard College | Spirooxindole inhibitors of aurora kinase |
JP2010527954A (en) * | 2007-05-23 | 2010-08-19 | エフ.ホフマン−ラ ロシュ アーゲー | Spiroindolinone derivatives |
JP2011506524A (en) * | 2007-12-19 | 2011-03-03 | エフ.ホフマン−ラ ロシュ アーゲー | Spiroindolinone derivatives |
WO2009151069A1 (en) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | Imidazothiazole derivative having 4,7-diazaspiro[2.5]octane ring structure |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
AU2009294673B2 (en) * | 2008-09-18 | 2014-08-14 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
CN102159207A (en) * | 2008-09-18 | 2011-08-17 | 霍夫曼-拉罗奇有限公司 | Substituted pyrrolidine-2-carboxamides |
RU2506257C2 (en) * | 2008-09-18 | 2014-02-10 | Ф.Хоффманн-Ля Рош Аг | Substituted pyrrolidine-2-carboxamides |
JP2012502940A (en) * | 2008-09-18 | 2012-02-02 | エフ.ホフマン−ラ ロシュ アーゲー | Substituted pyrrolidine-2-carboxamide |
KR101380013B1 (en) | 2008-09-18 | 2014-04-10 | 에프. 호프만-라 로슈 아게 | Substituted pyrrolidine-2-carboxamides |
WO2010031713A1 (en) | 2008-09-18 | 2010-03-25 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
US9458178B2 (en) | 2008-10-17 | 2016-10-04 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
US8263606B2 (en) | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
US8415370B2 (en) | 2008-10-17 | 2013-04-09 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their uses as therapeutic agents |
US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
US8916580B2 (en) | 2008-10-17 | 2014-12-23 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
US7928233B2 (en) | 2009-02-10 | 2011-04-19 | Hoffmann-La Roche Inc. | Spiroindolinone pyridine derivatives |
US8217051B2 (en) | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
US9480677B2 (en) | 2009-06-29 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents |
US8883840B2 (en) | 2009-06-29 | 2014-11-11 | Xenon Pharmaceuticals Inc. | Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents |
US8450358B2 (en) | 2009-06-29 | 2013-05-28 | Xenon Pharmaceuticals Inc. | Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents |
US8445696B2 (en) | 2009-10-14 | 2013-05-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
US9260446B2 (en) | 2009-10-14 | 2016-02-16 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
US9695185B2 (en) | 2009-10-14 | 2017-07-04 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
US8742109B2 (en) | 2009-10-14 | 2014-06-03 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
WO2011045257A1 (en) * | 2009-10-14 | 2011-04-21 | F. Hoffmann-La Roche Ag | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions |
WO2011061139A1 (en) * | 2009-11-17 | 2011-05-26 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
JP2013512869A (en) * | 2009-12-02 | 2013-04-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Spiroindolinone pyrrolidine |
KR101418191B1 (en) | 2009-12-02 | 2014-07-09 | 에프. 호프만-라 로슈 아게 | Spiroindolinone pyrrolidines |
WO2011067185A1 (en) * | 2009-12-02 | 2011-06-09 | F. Hoffmann-La Roche Ag | Spiroindolinone pyrrolidines |
AU2010326855B2 (en) * | 2009-12-02 | 2015-10-29 | F. Hoffmann-La Roche Ag | Spiroindolinone pyrrolidines |
KR101461298B1 (en) * | 2010-02-09 | 2014-11-28 | 에프. 호프만-라 로슈 아게 | Substituted pyrrolidine-2-carboxamides |
WO2011098398A1 (en) * | 2010-02-09 | 2011-08-18 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
CN102753522A (en) * | 2010-02-09 | 2012-10-24 | 霍夫曼-拉罗奇有限公司 | Substituted pyrrolidine-2-carboxamides |
AU2011214506B2 (en) * | 2010-02-09 | 2014-04-17 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
CN102753522B (en) * | 2010-02-09 | 2013-11-27 | 霍夫曼-拉罗奇有限公司 | Substituted pyrrolidine-2-carboxamides |
AU2011214506C1 (en) * | 2010-02-09 | 2014-07-17 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
WO2011101297A1 (en) * | 2010-02-17 | 2011-08-25 | F. Hoffmann-La Roche Ag | Substituted spiroindolinones |
US9504671B2 (en) | 2010-02-26 | 2016-11-29 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
WO2011134925A1 (en) | 2010-04-28 | 2011-11-03 | F. Hoffmann-La Roche Ag | Spiroindolinone pyrrolidines |
WO2012022707A1 (en) * | 2010-08-18 | 2012-02-23 | F. Hoffmann-La Roche Ag | Substituted heteroaryl spiropyrrolidine mdm2 antagonists |
WO2012034954A1 (en) * | 2010-09-15 | 2012-03-22 | F. Hoffmann-La Roche Ag | Substituted hexahydropyrrolo [1, 2 - c] imidazolones useful as mdm2 inhibitors |
WO2012038307A1 (en) * | 2010-09-20 | 2012-03-29 | F. Hoffmann-La Roche Ag | Spiro substituted pyrrolo[1,2-c]imidazole derivatives useful as mdm2 inhibitors |
US9381238B2 (en) | 2010-11-05 | 2016-07-05 | University Of Dundee | Method for improving the production of influenza viruses and vaccine seeds |
EP2684880A4 (en) * | 2011-03-10 | 2014-07-23 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivative |
TWI494312B (en) * | 2011-03-10 | 2015-08-01 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivatives |
CN105753872B (en) * | 2011-03-10 | 2017-11-17 | 第一三共株式会社 | Two spiropiperidines or spiropyrrolidines derivatives |
CN103635473A (en) * | 2011-03-10 | 2014-03-12 | 第一三共株式会社 | Dispiropyrrolidine derivative |
KR101779644B1 (en) | 2011-03-10 | 2017-09-18 | 다이이찌 산쿄 가부시키가이샤 | Dispiropyrrolidine derivatives |
CN105753872A (en) * | 2011-03-10 | 2016-07-13 | 第三共株式会社 | Dispiropyrrolidine Derivatives |
WO2012121361A1 (en) | 2011-03-10 | 2012-09-13 | 第一三共株式会社 | Dispiropyrrolidine derivative |
EP2684880A1 (en) * | 2011-03-10 | 2014-01-15 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivative |
JP5792279B2 (en) * | 2011-03-10 | 2015-10-07 | 第一三共株式会社 | Dispiropyrrolidine derivatives |
US8629133B2 (en) | 2011-03-10 | 2014-01-14 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivatives |
WO2012155066A2 (en) | 2011-05-11 | 2012-11-15 | Shaomeng Wang | Spiro-oxindole mdm2 antagonists |
EP2707372A4 (en) * | 2011-05-11 | 2014-10-22 | Univ Michigan | Spiro-oxindole mdm2 antagonists |
EP2707372A2 (en) * | 2011-05-11 | 2014-03-19 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
AU2012253339B2 (en) * | 2011-05-11 | 2016-03-31 | Sanofi | Spiro-oxindole MDM2 antagonists |
US9718831B2 (en) | 2012-09-06 | 2017-08-01 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
US10023578B2 (en) | 2012-09-06 | 2018-07-17 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
US10030030B2 (en) | 2012-09-06 | 2018-07-24 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
JPWO2014038606A1 (en) * | 2012-09-06 | 2016-08-12 | 第一三共株式会社 | Crystals of dispiropyrrolidine derivatives |
US9359368B2 (en) | 2012-09-06 | 2016-06-07 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
RU2647840C2 (en) * | 2012-09-06 | 2018-03-21 | Дайити Санкио Компани, Лимитед | Crystals of dipyropyrrolidine derivatives |
CN104812757B (en) * | 2012-09-06 | 2016-11-09 | 第一三共株式会社 | The crystal of two spiropiperidines or spiropyrrolidines derivants |
WO2014038606A1 (en) | 2012-09-06 | 2014-03-13 | 第一三共株式会社 | Crystal of dispiropyrrolidine derivative |
US9540386B2 (en) | 2012-09-06 | 2017-01-10 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
US9884871B2 (en) | 2012-09-06 | 2018-02-06 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
TWI586668B (en) * | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | Crystals of dispiropyrrolidine derivative |
US9745315B2 (en) | 2012-09-06 | 2017-08-29 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
CN104812757A (en) * | 2012-09-06 | 2015-07-29 | 第一三共株式会社 | Crystal of dispiropyrrolidine derivative |
US9718830B2 (en) | 2012-09-06 | 2017-08-01 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
KR20150048140A (en) | 2012-09-06 | 2015-05-06 | 다이이찌 산쿄 가부시키가이샤 | Crystal of dispiropyrrolidine derivative |
US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
CN103435622A (en) * | 2013-07-31 | 2013-12-11 | 陕西科技大学 | Spiro indole diketopiperazine alkaloid, and synthesis method and application of spiro indole diketopiperazine alkaloid |
CN103435622B (en) * | 2013-07-31 | 2015-11-18 | 陕西科技大学 | A kind of spiro indole diketopiperazine Alkaloid and synthetic method thereof and application |
WO2015033974A1 (en) | 2013-09-04 | 2015-03-12 | 第一三共株式会社 | Method for producing spirooxindole derivative |
US11419870B2 (en) | 2014-06-26 | 2022-08-23 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
EP3160463B1 (en) | 2014-06-26 | 2020-10-21 | Novartis AG | Intermittent dosing of mdm2 inhibitor |
US10576064B2 (en) | 2014-07-03 | 2020-03-03 | Boehringer Ingelheim International Gmbh | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors |
WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
US10919913B2 (en) | 2014-08-21 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors |
US9682033B2 (en) | 2015-02-05 | 2017-06-20 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
CN107427501B (en) * | 2015-02-20 | 2023-12-01 | 第一三共株式会社 | Methods of treating cancer by combination use |
US10716790B2 (en) | 2015-02-20 | 2020-07-21 | Daiichi Sankyo Company, Limited | Method for treating cancer by combined use |
CN107427501A (en) * | 2015-02-20 | 2017-12-01 | 第三共株式会社 | Integrated processes for treating cancer |
RU2717238C2 (en) * | 2015-03-30 | 2020-03-19 | Мишн Терапьютикс Лимитед | Compounds of 1-cyano-pyrrolidines as usp30 inhibitors |
US10485794B2 (en) | 2015-04-13 | 2019-11-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of MDM2 inhibitor and BTK inhibitor |
US11261171B1 (en) | 2015-09-29 | 2022-03-01 | Astex Therapeutics Limited | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity |
US10981898B2 (en) | 2015-09-29 | 2021-04-20 | Astex Therapeutics Limited | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity |
WO2017060431A1 (en) | 2015-10-09 | 2017-04-13 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
US10882866B1 (en) | 2015-10-09 | 2021-01-05 | Boehringer Ingelheim International Gmbh | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors |
US10717742B2 (en) | 2015-10-09 | 2020-07-21 | Boehringer Ingelheim International Gmbh | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors |
RU2743432C2 (en) * | 2016-04-06 | 2021-02-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Mdm2 protein destructors |
US11192898B2 (en) | 2016-04-06 | 2021-12-07 | The Regents Of The University Of Michigan | MDM2 protein degraders |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
WO2018074387A1 (en) | 2016-10-17 | 2018-04-26 | 第一三共株式会社 | Combination therapy method using mdm2 inhibitor and dna methyltransferase inhibitor |
KR20190068544A (en) | 2016-10-17 | 2019-06-18 | 다이이찌 산쿄 가부시키가이샤 | Combination treatment of MDM2 inhibitor with DNA methyltransferase inhibitor |
US11236047B2 (en) | 2017-03-28 | 2022-02-01 | Astex Therapeutics Limited | Combination of isoindolinone derivatives with SGI-110 |
US11603367B2 (en) | 2017-03-28 | 2023-03-14 | Astex Therapeutics Limited | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them |
CN112876488B (en) * | 2021-02-18 | 2021-12-21 | 苏州大学 | Spiro indoline derivative and preparation method and application thereof |
CN112876488A (en) * | 2021-02-18 | 2021-06-01 | 苏州大学 | Spiro indoline derivative and preparation method and application thereof |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
CN101160314A (en) | 2008-04-09 |
CN102627649B (en) | 2015-03-25 |
EA014445B1 (en) | 2010-12-30 |
EA019566B1 (en) | 2014-04-30 |
EA201001255A1 (en) | 2011-02-28 |
NO20074853L (en) | 2007-11-21 |
JP5248866B2 (en) | 2013-07-31 |
EP1856123B1 (en) | 2016-02-17 |
AU2006216780A1 (en) | 2006-08-31 |
KR20070108917A (en) | 2007-11-13 |
AU2006216780B2 (en) | 2010-04-01 |
CA2598690C (en) | 2011-11-15 |
CN102627649A (en) | 2012-08-08 |
JP5638023B2 (en) | 2014-12-10 |
AU2010202759A1 (en) | 2010-07-22 |
CA2752738C (en) | 2014-05-27 |
EP1856123A4 (en) | 2010-12-29 |
EP1856123A2 (en) | 2007-11-21 |
KR100944301B1 (en) | 2010-02-24 |
WO2006091646A3 (en) | 2006-11-30 |
EA200701771A1 (en) | 2008-06-30 |
CA2752738A1 (en) | 2006-08-31 |
BRPI0609172A2 (en) | 2010-02-23 |
AU2006216780B8 (en) | 2010-04-22 |
JP2008531504A (en) | 2008-08-14 |
MX2007010272A (en) | 2008-03-12 |
AU2010202759B2 (en) | 2012-07-19 |
CN101160314B (en) | 2012-05-23 |
CA2598690A1 (en) | 2006-08-31 |
JP2012162550A (en) | 2012-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1856123A2 (en) | Small molecule inhibitors of mdm2 and uses thereof | |
US7759383B2 (en) | Small molecule inhibitors of MDM2 and the uses thereof | |
EP2063887A2 (en) | New small molecule inhibitors of mdm2 and the uses thereof | |
JP5416089B2 (en) | Diazo bicyclic SMAC mimics and uses thereof | |
EP2707372A2 (en) | Spiro-oxindole mdm2 antagonists | |
NO341896B1 (en) | Intermediates for the preparation of bivalent Smac mimetic agents | |
EP1856083A2 (en) | Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof | |
WO2009126947A2 (en) | Heteroaryl-substituted bicyclic smac mimetics and the uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680012907.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007556414 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2598690 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/010272 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6787/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 561215 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006216780 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006735754 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077021939 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200701771 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2006216780 Country of ref document: AU Date of ref document: 20060222 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0609172 Country of ref document: BR Kind code of ref document: A2 |